Written question asked by Baroness Brown of Silvertown (Labour) on Friday, 1 December 2017, in the House of Commons. It was due for an answer on Tuesday, 5 December 2017. It was answered by Steve Brine (Conservative) on Monday, 11 December 2017 on behalf of the Department of Health.
Breast Cancer: Biosimilar Medicines
- Question
-
To ask the Secretary of State for Health, what discussions NHS England has had with (a) breast cancer charities and (b) patient groups on the introduction of the biosimilars of Herceptin, Trastuzumab.
- Answer
-
NHS England is working closely with the Cancer Vanguard and the Chemotherapy Clinical Reference Group to ensure all stakeholders, including charities and patient groups, are involved with the implementation of biosimilar trastuzumab.
Secondary information
- Type
- Written question
- Reference
- 117068
- Session
- 2017-19
- Subjects
- Breast cancer Biosimilar medicines
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2017-12-11 18:35:16 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/117068
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/117068
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/117068